Markets

Enanta Pharmaceuticals To Present Data For Zelicapavir, Oral, Once-Daily, N-Protein Inhibitor In Development For Treatment Of Respiratory Syncytial Virus At IDWeek 2026

Oct 13, 2026 · 07:03 AM ET· updated 53m ago

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for

Why It Matters

Enanta will show test results for a new virus medicine at a big conference. This gives investors a chance to learn if the drug is working well.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ENTA12.30

-0.20 (-1.60%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.